Non Small Cell Lung Cancer (NSCLC)

Stage I-III: Unresectable

Stage 1

LUN0071
Phase II/III:
Fresolimumab & Stereotactic Ablative Radiotherapy in Early Stage Non-Small Cell Lung Cancer
Pt: Diehn
Stanford
1st Priority

LUN0048
Phase II trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (SABR)
Pt: Diehn
Stanford
2nd Priority

KEY

- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Observation Study
- Enrollment on Hold
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu